---
layout: default
title: Bimekizumab
parent: 僅模型預測 (L5)
nav_order: 30
evidence_level: L5
indication_count: 0
---

# Bimekizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# BIMEKIZUMAB (DB12917): Repurposing Evaluation — Pending Critical Data

## One-Sentence Summary

BIMEKIZUMAB (DrugBank ID: DB12917) is a drug currently being assessed for repurposing potential; however, the current Evidence Pack does not contain original indication records, mechanism of action data, or TxGNN-predicted new indications. A complete repurposing evaluation cannot be performed until the two blocking data gaps — package insert content and MOA — are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — TFDA package insert not yet parsed |
| Predicted New Indication | Not available — TxGNN predictions not provided in this pack |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (insufficient data for assessment) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Taiwan Market Information

BIMEKIZUMAB currently has **no registered authorizations in Taiwan**. The TFDA query (2026-03-29) returned zero records. There are no approved product names, dosage forms, or indication texts available from the regulatory database.

---

## Safety Considerations

Safety data is not available in this Evidence Pack. The DDI query returned no results, and key warnings and contraindication data require parsing of the TFDA package insert (query log entry ID 4 reports a successful retrieval, but the content has not been extracted into the Evidence Pack).

> Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains two Blocking/High-severity data gaps — missing package insert content and missing mechanism of action — and no TxGNN predicted indications are present. There is currently no scientific basis on which to evaluate repurposing potential.

**To proceed, the following is needed:**

- [ ] **MOA data** (DG002 · High): Query DrugBank API for DB12917 to retrieve mechanism of action, pharmacodynamics, and drug categories
- [ ] **Package insert content** (DG001 · Blocking): Extract key warnings and contraindications from the TFDA package insert PDF (query log ID 4 indicates the document was retrieved successfully — parsing is the next step)
- [ ] **TxGNN predicted indications**: Run TxGNN inference for BIMEKIZUMAB and populate `predicted_indications` with disease candidates, scores, clinical trial links, and literature PMIDs
- [ ] **DDI data**: Re-query drug interaction database once MOA is confirmed, as interaction profiles often depend on drug class
- [ ] Re-generate this Evidence Pack at v5 once the above items are resolved
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

